Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma

被引:68
作者
Jazaeri, AA
Lu, K
Schmandt, R
Harris, CP
Rao, PH
Sotiriou, C
Chandramouli, GVR
Gershenson, DM
Liu, ET
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA
[2] Texas Childrens Canc Ctr, Dept Pediat, Houston, TX USA
[3] NCI, Ctr Canc Res, Gaithersburg, MD USA
关键词
ovarian cancer; grade; microarray; centrosome; 20q13;
D O I
10.1002/mc.10098
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In epithelial ovarian cancer, tumor grade is an independent prognosticator whose molecular determinants remain unknown. We investigated patterns of gene expression in well- and poorly differentiated serous papillary ovarian and peritoneal carcinomas with cDNA microarrays. A 6500-feature cDNA microarray was used for comparison of the molecular profiles of eight grade III and four grade I stage III serous papillary adenocarcinomas. With a modified F-test in conjunction with random permutations, 99 genes whose expression was significantly different between grade I and grade III tumors were identified (P < 0.01). A disproportionate number of these differentially expressed genes were located on the chromosomal regions 20q13 and all exhibited higher expression in grade III tumors. Interphase fluorescent in situ hybridization demonstrated 20q13 amplification in two of the four grade III and none of the three grade I tumors available for evaluation. Several centrosome-related genes also showed higher expression in grade III tumors. We propose a model in which tumor differentiation is inversely correlated with the overexpression of several oncogenes located on 20q13, a common amplicon in ovarian and numerous other cancers. Dysregulation of centrosome function is one potential mechanistic link between genetic/epigenetic changes and the poorly differentiated phenotype in ovarian cancer. Published 2003 Wiley-Liss, Inc.
引用
收藏
页码:53 / 59
页数:7
相关论文
共 37 条
[1]  
Bakshi N, 1998, ANAL QUANT CYTOL, V20, P215
[2]   Ovarian cancer:: an institutional review of patterns of care, health insurance and prognosis [J].
Balli, S ;
Fey, MF ;
Hänggi, W ;
Zwahlen, D ;
Berclaz, G ;
Dreher, E ;
Aebi, S .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (16) :2061-2068
[3]  
Bin OY, 1998, CELL GROWTH DIFFER, V9, P877
[4]  
Boveri T., 1929, ORIGIN MALIGNANT TUM, V7, P68
[5]   CAS, the human homologue of the yeast chromosome-segregation gene CSE1, in proliferation, apoptosis, and cancer [J].
Brinkmann, U .
AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (03) :509-513
[6]   Comprehensive genome sequence analysis of a breast cancer amplicon [J].
Collins, C ;
Volik, S ;
Kowbel, D ;
Ginzinger, D ;
Ylstra, B ;
Cloutier, T ;
Hawkins, T ;
Predki, P ;
Martin, C ;
Wernick, M ;
Kuo, WL ;
Alberts, A ;
Gray, JW .
GENOME RESEARCH, 2001, 11 (06) :1034-1042
[7]  
Cuthill S, 1999, GENE CHROMOSOME CANC, V26, P304, DOI 10.1002/(SICI)1098-2264(199912)26:4<304::AID-GCC4>3.0.CO
[8]  
2-1
[9]  
De Angelis PM, 1999, BRIT J CANCER, V80, P526
[10]   Centrosomal and cytoplasmic cdc2/cyclin B1 activation precedes nuclear mitotic events [J].
De Souza, CPC ;
Ellem, KAO ;
Gabrielli, BG .
EXPERIMENTAL CELL RESEARCH, 2000, 257 (01) :11-21